Peer-reviewed veterinary case report
Biomarkers linked to treatment success in dogs with small intestinal
By Yamazaki, Hiroki et al.Ā·Published in Veterinary and comparative oncologyĀ·2021Ā·College of Life, JapanĀ·View original on PubMed ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Assessment of biomarkers influencing treatment success on small intestinal lymphoma in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with localized small intestinal lymphoma (SIL) were treated with either surgery or chemotherapy to see which method worked better. The study looked at 84 dogs and found that the success of treatment could be influenced by specific biomarkers, Ki67 and MGMT. Dogs with higher Ki67 levels tended to do better with chemotherapy, while those with higher MGMT levels had better outcomes with surgery. This suggests that testing for these biomarkers can help veterinarians choose the best treatment for dogs with SIL.
People also search for: dog lymphoma treatment options Ā· small intestinal lymphoma in dogs Ā· Ki67 biomarker in dogs
Abstract
This study aimed to determine a reliable therapeutic biomarker for localized small intestinal lymphoma (SIL) in dogs based on clinical and histopathological features. We retrospectively investigated 84 dogs with localized SIL, including 36 dogs receiving surgery and 48 dogs receiving chemotherapy. The dogs receiving surgery were divided into two subgroups: 18 dogs (group 1) with overall survival (OS) <120 days (median OS) and 18 dogs (group 2) with OS ≥120 days. Correspondingly, the dogs receiving chemotherapy were divided into 24 dogs (group 3) with OS <98 days (median OS) and 24 dogs (group 4) with OS ≥98 days. Clinical, haematological, histopathological and immunohistochemical analyses were comparatively evaluated among the four subgroups. There was no significant difference in OS between the surgery and chemotherapy groups. In dogs receiving surgery, the rate of Ki67-positive cells was significantly increased in group 1 compared to group 2 and showed no significant difference between groups 3 and 4. In dogs receiving chemotherapy, the rate of O6-methylguanine-DNA methyltransferase (MGMT) was significantly higher in group 3 than in group 4 and showed no significant difference between groups 1 and 2. Additionally, our data showed that OS in dogs with higher Ki67 expression might be significantly increased by chemotherapy than by surgery, that of those with higher MGMT expression might be significantly increased by surgery than by chemotherapy, and Ki67 and MGMT were independent of each other. Indices of Ki67 and MGMT are suggested therapeutic biomarkers to determine the optimal first-line treatment for localized SIL in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32920923/